Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Category

Sub-category

Conference

ASCO 2023: Latest in mRCC

Dr Javier Puente, Dr Cristina Suárez, Prof Stéphane Oudard, Prof Viktor Grünwald

ASCO 2023: Latest in mRCC ( Dr Javier Puente, Dr Cristina Suárez, Prof Stéphane Oudard, Prof Viktor Grünwald )

Erdafitinib and current treatment landscape for advanced bladder cancer

Dr Yohann Loriot and Prof Arlene Siefker-Radtke

Erdafitinib and current treatment landscape for advanced bladder cancer ( Dr Yohann Loriot and Prof Arlene Siefker-Radtke )

Cabozantinib with nivolumab/ipilimumab shows superior efficacy compared to...

Dr Brian Van Tine - Washington University in St Louis, St Louis, USA

Cabozantinib with nivolumab/ipilimumab shows superior efficacy compared to cabozantinib alone in soft tissue sarcoma ( Dr Brian Van Tine - Washington University in St Louis, St Louis, USA )

Baseline liquid biopsy results in treatment efficacy of FOLFIRI/cetuximab in...

Prof Sebastian Stintzing - Universitätsmedizin Berlin, Berlin, Germany

Baseline liquid biopsy results in treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC ( Prof Sebastian Stintzing - Universitätsmedizin Berlin, Berlin, Germany )

Real-world behavioural restrictional practices of cancer patients

Dr Eliya Shahar - Tel Aviv University, Tel Aviv, Israel

Real-world behavioural restrictional practices of cancer patients ( Dr Eliya Shahar - Tel Aviv University, Tel Aviv, Israel )

Elranatamab shows efficacy in RRMM with prior BCMA-directed treatment

Prof Ajay Nooka - Winship Cancer Center of Emory University, Atlanta, USA

Elranatamab shows efficacy in RRMM with prior BCMA-directed treatment ( Prof Ajay Nooka - Winship Cancer Center of Emory University, Atlanta, USA )

Pembrolizumab improves OS in firstline treatment for unresectable advanced...

Dr Penelope Bradbury - Princess Margaret Cancer Centre, Toronto, Canada

Pembrolizumab improves OS in firstline treatment for unresectable advanced pleural mesothelioma ( Dr Penelope Bradbury - Princess Margaret Cancer Centre, Toronto, Canada )

Pembro plus chemo followed by resection and adjuvant pembro improves on...

Prof Heather Wakelee - Stanford Cancer Institute, Stanford, USA

Pembro plus chemo followed by resection and adjuvant pembro improves on standard of care for early NSCLC ( Prof Heather Wakelee - Stanford Cancer Institute, Stanford, USA )

Nivolumab-AVD reduces the risk of disease progression compared to brentuximab...

Dr Alex Herrera - City of Hope Comprehensive Cancer Center, Duarte, USA

Nivolumab-AVD reduces the risk of disease progression compared to brentuximab vedotin-AVD in advanced Hodgkin lymphoma ( Dr Alex Herrera - City of Hope Comprehensive Cancer Center, Duarte, USA )

PHE885 CAR-T cell therapy shows high response rates for r/r multiple myeloma in...

Prof Adam Sperling - Dana-Farber Cancer Institute, Boston, USA

PHE885 CAR-T cell therapy shows high response rates for r/r multiple myeloma in phase 1 ( Prof Adam Sperling - Dana-Farber Cancer Institute, Boston, USA )

HCC: Improvement in RFS for atezolizumab plus bevacizumab vs active...

Prof Masatoshi Kudo - Kindai University, Higashiōsaka, Japan

HCC: Improvement in RFS for atezolizumab plus bevacizumab vs active surveillance without compromising QoL ( Prof Masatoshi Kudo - Kindai University, Higashiōsaka, Japan )

Adding ribociclib to endocrine therapy shows an improvement in invasive disease...

Prof Dennis Slamon - UCLA, Los Angeles, USA

Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients ( Prof Dennis Slamon - UCLA, Los Angeles, USA )

More from ecancer